摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

西洛他唑 | 152044-53-6

中文名称
西洛他唑
中文别名
埃博霉素A;埃博霉素 A
英文名称
epithilone A
英文别名
(-)-Epothilone A;Epothilone A;epothilone B;epothilone-A;epothiloneA;epo A;(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
西洛他唑化学式
CAS
152044-53-6
化学式
C26H39NO6S
mdl
——
分子量
493.665
InChiKey
HESCAJZNRMSMJG-KKQRBIROSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    95℃
  • 比旋光度:
    D21 -47.1° (c = 1.0 in methanol)
  • 沸点:
    683.3±55.0 °C(Predicted)
  • 密度:
    1.143
  • 溶解度:
    氯仿(微溶)、乙酸乙酯(微溶)

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    34
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    138
  • 氢给体数:
    2
  • 氢受体数:
    8

ADMET

代谢
多溴联苯(PBBs)可以通过口服、吸入和皮肤途径被吸收。由于它们的亲脂性,尤其是高溴代的多溴联苯,倾向于在富含脂质的组织中积累,如肝脏、脂肪、皮肤和母乳。某些多溴联苯化合物通过由苯巴比妥诱导的细胞色素P-450类型的微粒体单加氧酶系统进行代谢。代谢速率可能取决于溴取代模式。低溴含量的多溴联苯同系物转化为主要在尿液中排出的羟基衍生物。高溴代同系物要么被保留,要么在粪便中不变排出。(L628)
PBBs can be absorbed via oral, inhalation, and dermal routes. Due to their lipophilic nature, PBBs, especially the highly brominated congeners, tend to accumulate in lipid-rich tissues such as the liver, adipose, skin, and breast milk. Certain PBB compounds are metabolized by the microsomal monooxygenase system catalyzed by cytochrome P-450 of the type induced by phenobarbital. The rate of metabolism may depends on the bromine substitution pattern. PBB congeners of low bromine content are transformed into hydroxylated derivatives that are predominately eliminated in the urine. Highly brominated congeners are either retained or excreted unchanged in the feces. (L628)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 毒性总结
多氯联苯(PBBs)的毒性机制因具体同系物而异。主要的相互作用被认为是涉及芳基烃受体(AhR)。PBBs与AhR结合并激活它,进而启动一系列基因的转录上调,影响生化途径和内分泌途径、细胞周期调节、形态发生、氧化应激反应以及各种其他过程。这导致PBBs特有的多种毒性反应。一些已知的诱导基因包括细胞色素P-450依赖性单加氧酶CYP1A1和CYP1A2。
The exact mechanism of toxicty of PBBs varies depending on the specific congener. The predominant interaction is believed to involve the aryl hydrocarbon receptor (AhR). PBBs bind to and activate the AhR, which in turn initiates the transcriptional upregulation of a number of genes, affecting biochemical and endocrine pathways, cell cycle regulation, morphogenesis, oxidative stress response, and various other processes. This results in the numerous toxic responses characteristic of PBBs. Some of the known induced genes include the cytochrome P-450-dependent monooxygenases CYP1A1 and CYP1A2. (L628)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 致癌物分类
2A,可能对人类致癌。(L135)
2A, probably carcinogenic to humans. (L135)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 健康影响
PBB暴露可能会导致体重减轻、皮肤问题(如痤疮)、神经和免疫系统的影响,以及对肝脏、肾脏和甲状腺的影响。
PBB exposure may cause weight loss, skin disorders (such as acne), nervous and immune systems effects, and effects on the liver, kidneys, and thyroid gland. (L628)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 暴露途径
口服(L628);吸入(L628);皮肤给药(L628)
Oral (L628) ; inhalation (L628) ; dermal (L628)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 症状
PBB暴露的症状可能包括恶心、腹痛、食欲不振、关节痛、疲劳和虚弱。
Symptoms of PBB exposure may include nausea, abdominal pain, loss of appetite, joint pain, fatigue, and weakness. (L629)
来源:Toxin and Toxin Target Database (T3DB)

安全信息

  • WGK Germany:
    3
  • 储存条件:
    -20°C

SDS

SDS:c603bfefc7db2ad3c410df45be39482c
查看

制备方法与用途

埃博霉素(epothilone)是一类大环内酯类化合物,由德国国家生物技术中心的G. Höfle等人于1993年首次报道。这种化合物主要从粘细菌亚目的纤维堆囊菌菌株发酵液中分离得到,其主要组分是Epothilone A和B。

生物活性 Epothilone A是一种类似紫杉醇的微管稳定剂,EC0.01为2 μM。它能够诱导微管蛋白聚合,导致细胞周期停滞于G2-M期,并产生毒性作用,也能够诱导凋亡。其EC0.01值为2 μM。

靶点

Target Value
Tubulin 2 μM

体外研究 Epothilone A是在粘杆菌Sorangium cellulosum中发现的,是一种类似紫杉醇的微管稳定剂。它能够诱导微管蛋白聚合,导致细胞周期停滞于G2-M期,并产生毒性作用,也能够诱导凋亡。Epothilone A的EC0.01值为2 μM。在HCT116细胞中,有效抑制细胞增殖,IC50为4.4 nM;在KB3-1、KBV-1、Hela和Hs578T细胞中具有细胞毒性,IC50范围从13 nM到160 nM。Epothilone A比紫杉醇更易溶于水,并且能够与微管结合,其IC50值为2.3 μM。尽管Epothilone A和Taxol在药效团上不共享同一结构,但它们分别独立且特异性地利用各自微管蛋白的结合袋。

最新研究发现Aspergillus niger AS 3.739引起的Epothilone A微生物转化产生了几种代谢物,这些代谢物对MCF-7细胞具有毒性作用,但其IC50值非常高。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    埃博霉素C desoxyepothilone A 186692-73-9 C26H39NO5S 477.665
    —— (4S,7R,8S,9S,16S)-4,8-Dihydroxy-5,5,7,9-tetramethyl-16-[(E)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-1-ethenyl]-1-oxa-cyclohexadecen-13-en-2,6-dione —— C26H39NO5S 477.665
    —— (1S,3S,7S,10R,11S,12S,16R)-3-[(E)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-1-ethenyl]-11-hydroxy-7-(4-methoxybenzyloxy)-8,8,10,12-tetramethyl-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione 479485-03-5 C34H47NO7S 613.816
    —— carbonic acid (7S)-(tert-butyl-dimethyl-silanyloxy)-8,8,(10R,12S)-tetramethyl-(3S)-[1-methyl-(2E)-(2-methyl-thiazol-4-yl)-vinyl]-5,9-dioxo-4,17-dioxa-bicyclo[14.1.0]heptadec-(11S)-yl ester 2,2,2-trichloro-ethyl ester 342607-19-6 C35H54Cl3NO8SSi 783.326
    —— (1S)-1-[(E)-1-Methyl-2-(2-methyl-1,3-thiazol-4-yl)-1-ethenyl]-3-butenyl (3S,6R,7S,8S)-3,7-di-[tert-butyldimethylsilyloxy]-4,4,6,8-tetramethyl-5-oxo-12-tridecenoate 188259-76-9 C40H71NO5SSi2 734.244
    —— (3S,6R,7S,8S)-(S,E)-2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-dien-3-yl 3-((tert-butyldimethylsilyl)oxy)-7-hydroxy-4,4,6,8-tetramethyl-5-oxotridec-12-enoate 187283-48-3 C34H57NO5SSi 619.982
    —— (4S,7R,8S,16S)-8-hydroxy-4-(4-methoxybenzyloxy)-5,5,7,9-tetramethyl-16-[(E)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-1-ethenyl]-1-oxacyclohexadec-13-en-2,6-dione 479485-07-9 C34H47NO6S 597.816
    —— (4S,7R,8S,9S,16S)-4,8-bis(tert-butyldimethylsilyloxy)-5,5,7,9-tetramethyl-16-[(E)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-1-vinyl]-(13Z)-1-oxacyclohexadec-13-ene-2,6-dione 186692-84-2 C38H67NO5SSi2 706.191
    —— (4S,7R,8S,9S,13Z,16S)-4-[tert-butyl(dimethyl)silyl]oxy-8-hydroxy-5,5,7,9-tetramethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione 187283-49-4 C32H53NO5SSi 591.928
    —— (4S,7R,8S,9S,16S)-4,8-Di-tert-butyldimethylsilyloxy-5,5,7,9-tetramethyl-16-[(E)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-1-ethenyl]-1-oxa-13-cyclohexadecen-2,6-dione 204194-92-3 C38H67NO5SSi2 706.191
    • 1
    • 2
    • 3
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    埃博霉素B epothilone B 152044-54-7 C27H41NO6S 507.692
    —— epothilone E —— C26H39NO7S 509.664
    —— (4S,7R,8S,9S,16S)-4,8,13,14-Tetrahydroxy-5,5,7,9-tetramethyl-16-[(E)-1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-oxacyclohexadecane-2,6-dione 198571-40-3 C26H41NO7S 511.68
    —— epothilone F —— C27H41NO7S 523.691
    —— (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-3-((E)-1-(2-(methoxymethyl)thiazol-4-yl)prop-1-en-2-yl)-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione 289494-45-7 C27H41NO7S 523.691
    —— 4-((E)-2-((1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-5,9-dioxo-4,17-dioxabicyclo[14.1.0]heptadecan-3-yl)prop-1-en-1-yl)-2-methylthiazole 3-oxide 212321-22-7 C26H39NO7S 509.664
    —— [1R,3S(E),7R,10S,11S,12R,16R]-11-hydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-5,9-dioxo-4,17-dioxa-bicyclo[14.1.0]heptadecane-7-carbonitrile —— C27H38N2O5S 502.675
    —— [1R,3S(E),7S,10S,11S,12R,16R]-11-hydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-5,9-dioxo-4,17-dioxa-bicyclo[14.1.0]heptadecane-7-carbonitrile —— C27H38N2O5S 502.675
    —— bis-TES-epothilone A 247232-06-0 C38H67NO6SSi2 722.19
    埃博霉素C desoxyepothilone A 186692-73-9 C26H39NO5S 477.665
    • 1
    • 2
    • 3
    • 4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON
    申请人:BIOCAD JOINT STOCK CO
    公开号:WO2018092047A1
    公开(公告)日:2018-05-24
    The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.
    本发明涉及一种新的化合物,其化学式为I:或其药学上可接受的盐、溶剂化合物或立体异构体,其中:V1为C或N,V2为C(R2)或N,如果V1为C,则V2为N,如果V1为C,则V2为C(R2),或者如果V1为N,则V2为C(R2);每个n,k独立地为0或1;每个R2,R11独立地为H,D,Hal,CN,NR'R",C(O)NR'R",C1-C6烷氧基;R3为H,D,羟基,C(O)C1-C6烷基,C(O)C2-C6烯基,C(O)C2-C6炔基,C1-C6烷基;R4为H,Hal,CN,CONR'R",羟基,C1-C6烷基,C1-C6烷氧基;L为CH2,NH,O或化学键;R1从包括的片段组中选择:片段1,片段2,片段3,每个A1,A2,A3,A4独立地为CH,N,CHal;每个A5,A6,A7,A8,A9独立地为C,CH或N;R5为H,CN,Hal,CONR'R",C1-C6烷基,未取代或被一个或多个卤素取代;每个R'和R"独立地从包括H,C1-C6烷基,C1-C6环烷基,芳基的组中选择;R6从组中选择:[化学式II]每个R7,R8,R9,R10独立地为乙烯基,甲基乙炔基;Hal为CI,Br,I,F,具有布鲁顿酪氨酸激酶(Btk)抑制剂的性质,以及含有这种化合物的药物组合物,以及它们作为治疗疾病和紊乱的药物的用途。
  • [EN] BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
    申请人:PFIZER
    公开号:WO2014068527A1
    公开(公告)日:2014-05-08
    Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)
    本文披露了一种与Bruton's酪氨酸激酶(BTK)形成共价键的化合物。公开了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。公开了使用BTK抑制剂的方法,单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症,包括淋巴瘤,以及炎症性疾病或症状的方法。 (化学式I)
  • [EN] PROCESSES FOR MAKING TRIAZOLO[4,5D] PYRAMIDINE DERIVATIVES AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉS DE PREPARATION DE DÉRIVÉS DE TRIAZOLO [4,5 D] PYRIMIDINE ET INTERMÉDIAIRES DE CEUX-CI
    申请人:CORVUS PHARMACEUTICALS INC
    公开号:WO2018183965A1
    公开(公告)日:2018-10-04
    Provided herein are, inter alia, methods for making triazolo[4,5]pyramidine derivatives and intermediates thereof that are useful for treating diseases.
    本文提供了制备三氮杂[4,5]吡啶衍生物及其中间体的方法,这些衍生物对治疗疾病有用。
  • [EN] SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF<br/>[FR] LIEURS AUTO-IMMOLABLES CONTENANT DES DÉRIVÉS D'ACIDE MANDÉLIQUE, CONJUGUÉS MÉDICAMENT-LIGAND POUR THÉRAPIES CIBLÉES, ET LEURS UTILISATIONS
    申请人:ASANA BIOSCIENCES LLC
    公开号:WO2015038426A1
    公开(公告)日:2015-03-19
    The invention provides a therapeutic drug and targeting conjugate, pharmaceutical compositions containing these conjugates in pharmaceutical composition, and uses of these conjugates in anti-neoplastic and other therapeutic regimens. Also provided are novel intermediates thereof. The conjugates provide a therapeutic drug fragment or prodrug fragment bound to a targeting moiety via a linker which comprises a substrate cleavable by a protease such as Cathepsin B. The targeting moiety is a ligand which targets a cell surface molecule, such as a cell surface receptor on an anti-neoplastic cell. The ligand may function solely as a targeting moiety or may itself have a therapeutic effect. Following administration of the therapeutic drug and targeting conjugate of formula I and exposure of the conjugate to the protease specific for the substrate, the linker is cleaved and the targeting moiety is separated from the conjugate, which causes the drug fragment or prodrug fragment to convert to the drug or prodrug. The recited conjugates are useful in anti-neoplastic therapies. Also provided are methods of making the therapeutic drug and targeting conjugates and intermediates thereof, and kits comprising the therapeutic drug and targeting conjugates.
    该发明提供了一种治疗药物和靶向共轭物,包含这些共轭物的药物组合物,以及这些共轭物在抗肿瘤和其他治疗方案中的用途。还提供了其新颖的中间体。这些共轭物通过一个由蛋白酶如半胱氨酸蛋白酶B可切割的底物组成的连接物将治疗药物片段或前药片段与靶向基团结合。靶向基团是一个以细胞表面分子为靶点的配体,例如抗肿瘤细胞上的细胞表面受体。该配体可能仅作为靶向基团,也可能本身具有治疗效果。在给药公式I的治疗药物和靶向共轭物并使共轭物暴露于特异于底物的蛋白酶的情况下,连接物被切割,靶向基团与共轭物分离,导致药物片段或前药片段转化为药物或前药。所述的共轭物在抗肿瘤疗法中很有用。还提供了制备治疗药物和靶向共轭物及其中间体的方法,以及包含治疗药物和靶向共轭物的试剂盒。
  • [EN] TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY<br/>[FR] COMPOSÉS TRIAZOLES TRICYCLIQUES MODULANT L'ACTIVITÉ HSP90
    申请人:SYNTA PHARMACEUTICALS CORP
    公开号:WO2009139916A1
    公开(公告)日:2009-11-19
    The present invention relates to substituted tricyclic triazole compounds and compositions comprising substituted tricyclic triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a compound of the invention, or a composition comprising such a compound.
    本发明涉及替代三环三唑化合物和包含替代三环三唑化合物的组合物。该发明还涉及在需要的受体中抑制Hsp90活性的方法,以及预防或治疗高增殖性疾病(如癌症)的方法,其中包括向受体施用本发明的化合物或包含这种化合物的组合物。
查看更多